These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 26775180)

  • 1. Changes in lipid and carbohydrate metabolism under mTOR- and calcineurin-based immunosuppressive regimen in adult patients after liver transplantation.
    Zimmermann A; Zobeley C; Weber MM; Lang H; Galle PR; Zimmermann T
    Eur J Intern Med; 2016 Apr; 29():104-9. PubMed ID: 26775180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. De novo hepatic steatosis drives atherogenic risk in liver transplantation recipients.
    Idowu MO; Chhatrala R; Siddiqui MB; Driscoll C; Stravitz RT; Sanyal AJ; Bhati C; Sargeant C; Luketic VA; Sterling RK; Contos M; Matherly S; Puri P; Siddiqui MS
    Liver Transpl; 2015 Nov; 21(11):1395-402. PubMed ID: 26228654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia.
    Kostapanos MS; Milionis HJ; Filippatos TD; Nakou ES; Bairaktari ET; Tselepis AD; Elisaf MS
    Clin Ther; 2007 Jul; 29(7):1403-14. PubMed ID: 17825691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurological complications after liver transplantation as a consequence of immunosuppression: univariate and multivariate analysis of risk factors.
    Rompianesi G; Montalti R; Cautero N; De Ruvo N; Stafford A; Bronzoni C; Ballarin R; De Pietri L; Di Benedetto F; Gerunda GE
    Transpl Int; 2015 Jul; 28(7):864-9. PubMed ID: 25790037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of serum atherogenic risk in liver transplant recipients: Role of lipoproteins and metabolic and inflammatory markers.
    Chhatrala R; Siddiqui MB; Stravitz RT; Driscoll C; Sanyal A; Sargeant C; Luketic V; Sharma A; Sterling R; Matherly S; Puri P; Siddiqui MS
    Liver Transpl; 2015 May; 21(5):623-30. PubMed ID: 25762084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Immunosuppressive Treatment on Carotid Atherosclerosis in Renal Transplant Recipients.
    Szymczak M; Kluz J; Małecki R; Wątorek E; Obremska M; Głuszek M; Klinger M; Boratyńska M
    Transplant Proc; 2016 Jun; 48(5):1626-9. PubMed ID: 27496459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alterations in lipid and carbohydrate metabolism in patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
    Zimmermann A; Grigorescu-Sido P; AlKhzouz C; Patberg K; Bucerzan S; Schulze E; Zimmermann T; Rossmann H; Geiss HC; Lackner KJ; Weber MM
    Horm Res Paediatr; 2010; 74(1):41-9. PubMed ID: 20395657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma.
    Rodríguez-Perálvarez M; Tsochatzis E; Naveas MC; Pieri G; García-Caparrós C; O'Beirne J; Poyato-González A; Ferrín-Sánchez G; Montero-Álvarez JL; Patch D; Thorburn D; Briceño J; De la Mata M; Burroughs AK
    J Hepatol; 2013 Dec; 59(6):1193-9. PubMed ID: 23867318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid profile changes during the first year after kidney transplantation: risk factors and influence of the immunosuppressive drug regimen.
    Spinelli GA; Felipe CR; Park SI; Mandia-Sampaio EL; Tedesco-Silva H; Medina-Pestana JO
    Transplant Proc; 2011 Dec; 43(10):3730-7. PubMed ID: 22172836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apolipoprotein A-I and B levels, dyslipidemia and metabolic syndrome in south-west Chinese women with PCOS.
    Zhang J; Fan P; Liu H; Bai H; Wang Y; Zhang F
    Hum Reprod; 2012 Aug; 27(8):2484-93. PubMed ID: 22674204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of plasma small dense LDL cholesterol with PCSK9 levels in patients with angiographically proven coronary artery disease.
    Zhang Y; Xu RX; Li S; Zhu CG; Guo YL; Sun J; Li JJ
    Nutr Metab Cardiovasc Dis; 2015 Apr; 25(4):426-33. PubMed ID: 25770756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies.
    Roth EM; Rosenson RS; Jones PH; Davidson MH; Kelly MT; Setze CM; Lele A; Thakker K
    J Clin Lipidol; 2012; 6(6):534-44. PubMed ID: 23312049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of chronic rejection in liver graft recipients receiving immunosuppression with low-dose calcineurin inhibitors.
    Barbier L; Garcia S; Cros J; Borentain P; Botta-Fridlund D; Paradis V; Le Treut YP; Hardwigsen J
    J Hepatol; 2013 Dec; 59(6):1223-30. PubMed ID: 23933266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An observational study of ezetimibe in cardiac transplant recipients receiving calcineurin inhibitors.
    Makkar KM; Sanoski CA; Goldberg LR; Spinler SA
    Ann Pharmacother; 2013 Nov; 47(11):1457-62. PubMed ID: 24285762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluvastatin/fenofibrate vs. simvastatin/ezetimibe in patients with metabolic syndrome: different effects on LDL-profiles.
    Winkler K; Schewe T; Pütz G; Odünc N; Schäfer G; Siegel E; Geisen U; Abletshauser C; Hoffmann MM
    Eur J Clin Invest; 2009 Jun; 39(6):463-70. PubMed ID: 19397693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
    Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
    Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Malignancies after heart transplantation: incidence, risk factors, and effects of calcineurin inhibitor withdrawal.
    Doesch AO; Müller S; Konstandin M; Celik S; Kristen A; Frankenstein L; Ehlermann P; Sack FU; Katus HA; Dengler TJ
    Transplant Proc; 2010 Nov; 42(9):3694-9. PubMed ID: 21094840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An mTOR-inhibitor-based protocol and calcineurin inhibitor (CNI)-free treatment in kidney transplant recipients from donors after cardiac death: good renal function, but high incidence of conversion to CNI.
    Sánchez-Escuredo A; Diekmann F; Revuelta I; Esforzado N; Ricart MJ; Cofán F; Torregrosa JV; Peri L; Ruiz Á; Campistol JM; Oppenheimer F
    Transpl Int; 2016 Mar; 29(3):362-8. PubMed ID: 26678359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small Dense Low-Density Lipoprotein Cholesterol Predicts Cardiovascular Events in Liver Transplant Recipients.
    Siddiqui MB; Arshad T; Patel S; Lee E; Albhaisi S; Sanyal AJ; Stravitz RT; Driscoll C; Sterling RK; Reichman T; Bhati C; Siddiqui MS
    Hepatology; 2019 Jul; 70(1):98-107. PubMed ID: 30672598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid profile and cardiovascular risk factors in pediatric liver transplant recipients.
    Roblin E; Dumortier J; Di Filippo M; Collardeau-Frachon S; Sassolas A; Peretti N; Serusclat A; Rivet C; Boillot O; Lachaux A
    Pediatr Transplant; 2016 Mar; 20(2):241-8. PubMed ID: 26750745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.